相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Forging New Scaffolds from Old: Combining Scaffold Hopping and Hierarchical Virtual Screening for Identifying Novel Bcl-2 Inhibitors
Vishnupriya Kanakaveti et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Richard W. Birkinshaw et al.
NATURE COMMUNICATIONS (2019)
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Piers Blombery et al.
CANCER DISCOVERY (2019)
Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
Touko Inao et al.
Oncotarget (2018)
BH4-mimetics and -antagonists: an emerging class of Bcl-2 protein modulators for cancer therapy
Adrien Nougarède et al.
Oncotarget (2018)
Importance of functional groups in predicting the activity of small molecule inhibitors for Bcl-2 and Bcl-xL
Vishnupriya Kanakaveti et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2017)
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
Stephen K. Tahir et al.
BMC CANCER (2017)
PRIDE Inspector Toolsuite: Moving Toward a Universal Visualization Tool for Proteomics Data Standard Formats and Quality Assessment of ProteomeXchange Datasets
Yasset Perez-Riverol et al.
MOLECULAR & CELLULAR PROTEOMICS (2016)
Covalent docking using autodock: Two-point attractor and flexible side chain methods
Giulia Bianco et al.
PROTEIN SCIENCE (2016)
BCL-2 family proteins as regulators of mitochondria metabolism
Atan Gross
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
The BCL-2 protein family, BH3-mimetics and cancer therapy
A. R. D. Delbridge et al.
CELL DEATH AND DIFFERENTIATION (2015)
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?
Michelle M. Williams et al.
ONCOTARGET (2015)
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2
Andrew R. Lavik et al.
ONCOTARGET (2015)
BH4 domain of Bcl-2 as a novel target for cancer therapy
Zhiqing Liu et al.
DRUG DISCOVERY TODAY (2015)
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
Vicente Fresquet et al.
BLOOD (2014)
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
Brian D. Lehmann et al.
JOURNAL OF PATHOLOGY (2014)
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Peter E. Czabotar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Justin M. Balko et al.
CANCER DISCOVERY (2014)
Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
T. M. A. Abdel-Fatah et al.
ANNALS OF ONCOLOGY (2013)
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Francois Vaillant et al.
CANCER CELL (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
BH3 profiling in whole cells by fluorimeter or FACS
Jeremy Ryan et al.
METHODS (2013)
ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells
Ricardo Parrondo et al.
PEERJ (2013)
Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design
W. Eiermann et al.
BREAST (2012)
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Samantha R. Oakes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A clinically relevant gene signature in triple negative and basal-like breast cancer
Achim Rody et al.
BREAST CANCER RESEARCH (2011)
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
S-J Dawson et al.
BRITISH JOURNAL OF CANCER (2010)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
Complex landscapes of somatic rearrangement in human breast cancer genomes
Philip J. Stephens et al.
NATURE (2009)
Bcl-2 family proteins and cancer
K. W. Yip et al.
ONCOGENE (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-κB and CXC chemokines
E Karl et al.
CANCER RESEARCH (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
分享论文
